Methods
Our Pediatric Hematology-Oncology and Stem Cell Transplantation Center
has a comprehensive and large database of all patients and donors. In
this center, transplantations were performed using the BM product
obtained by administering G-CSF to healthy donors in order to increase
the number of collected total nucleated cells (TNC) and CD34 cells for
some patients. The data obtained with the products collected from the BM
of healthy donors after G-CSF administration were analyzed in detail.
Three different products were used as G-CSF: biosimilar filgrastim
(Leucostim®) (n=29), original filgrastim (Neupogen®) (n=30), and
lenograstim (Granocyte®) (n=30). These G-CSFs were compared with one
another and with the control group (n=30). All donors were treated with
a standard institutional protocol. Approval for the study was obtained
from our local institutional review board.